• Refine Query
  • Source
  • Publication year
  • to
  • Language
  • 1
  • Tagged with
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • About
  • The Global ETD Search service is a free service for researchers to find electronic theses and dissertations. This service is provided by the Networked Digital Library of Theses and Dissertations.
    Our metadata is collected from universities around the world. If you manage a university/consortium/country archive and want to be added, details can be found on the NDLTD website.
1

Prepara??o e caracteriza??o de sistemas emulsionados lipidicos contendo praziquantel

Araujo, Margarete Moreno de 21 March 2013 (has links)
Made available in DSpace on 2014-12-17T14:16:35Z (GMT). No. of bitstreams: 1 MargareteMA_DISSERT.pdf: 2404421 bytes, checksum: ab50d77fe2623a656273511b601f292f (MD5) Previous issue date: 2013-03-21 / Coordena??o de Aperfei?oamento de Pessoal de N?vel Superior / Praziquantel (PRZ) is the main drug used for treatment of schistosomiasis in Brazil. It is administered by oral rout as tablets. However, has low aqueous solubility which limits this therapeutic success dosage form and availability of liquid forms. The emulsion systems have great potential and represent an interesting strategy to increase the solubility of drugs. The aim of study was the development and characterization of lipid-emulsified liquid systems of the type oil in water (O / W), the base of soybean oil as the internal phase stabilized by surfactants pair Tween? 80 and Span? 80, for improving the phase biopharmaceutical of PRZ. After selecting the best value of Hydrophilic-Lipophilic Balance (HLB = 11), the parameters of the preparation of the formulations were optimized emulsification technique. The emulsions were successfully obtained; the liquid forms provided exhibited Newtonian behavior and an increase in solubility of PRZ higher than 20 times. The accelerated stability study demonstrated the stability of the emulsions and the effect of cosurfactants investigated. The study of the dynamics of interaction between components in the diagram showed pseudoternary phase regions to obtain O/W emulsions, whereas the study of the interaction of the components and their effect on system structure and the efficiency of incorporation of the drug led to systems with an amount of soluble drug even higher (about 1.5%), which demonstrates the potential of this new input mainly for the treatment of schistosomiasis, which resulted in the filing of patent BR 10 2013 0004 55 3 / O praziquantel (PRZ) ? o f?rmaco de escolha para tratamento da esquistossomose no Brasil e est? dispon?vel comercialmente para administra??o oral na forma de comprimidos. No entanto, possui baixa solubilidade aquosa, o que limita o sucesso terap?utico desta forma farmac?utica e a disponibiliza??o de formas l?quidas. Os sistemas emulsionados lip?dicos t?m grande potencial para aumento da solubiliza??o de f?rmacos lipof?licos, sendo, ent?o, uma estrat?gia interessante para tal finalidade. O objetivo do presente estudo foi o desenvolvimento e a caracteriza??o de sistemas l?quidos emulsionados lip?dicos do tipo ?leo em ?gua (O/A), a base de ?leo de soja como fase interna estabilizada pelo par de tensoativos Tween? 80 e Span? 80, para melhorar a fase biofarmac?utica do PRZ. Depois de selecionar o melhor valor do Equil?brio Hidr?filo-Lip?filo (EHL=11), os par?metros de prepara??o das formula??es pela t?cnica de emulsifica??o foram otimizados. As emuls?es foram obtidas com sucesso, as formas l?quidas apresentaram comportamento newtoniano e proporcionaram um aumento de solubilidade do PRZ superior a 20 vezes. O estudo de estabilidade acelerada demonstrou a estabilidade das emuls?es e o efeito dos cotensoativos investigados. O estudo da din?mica de intera??o entre os componentes pelo diagrama pseudotern?rio de fase demonstrou regi?es de obten??o de emuls?es do tipo O/A, enquanto que o estudo da intera??o dos componentes e o seu efeito na estrutura dos sistemas e na efici?ncia de incorpora??o do f?rmaco levaram a obten??o de sistemas com uma quantidade de f?rmaco sol?vel ainda maior (cerca de 1,5%), o que demonstra o potencial deste novo insumo para o tratamento principalmente da esquistossomose, o qual resultou em um dep?sito de patente BR 10 2013 000455 3

Page generated in 0.0494 seconds